Morgan Stanley cuts Novo Nordisk to Underweight
Novo Nordisk shares fell more than 2% after Morgan Stanley lowered its rating to Underweight from Equal-weight, citing longer-term semaglutide risks and potential generic competition.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.